| E. COLI | Monitoring | 0 | N/A | Sep 9, 2025 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Arsenic | Health-Based | N/A | 0.011 | Jun 30, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Public Notice | Monitoring | N/A | N/A | Apr 6, 2025 | Active | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate-Nitrite | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Nitrate-Nitrite | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.012 | Mar 31, 2025 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Mar 31, 2025 | Resolved | N/A |
| Public Notice | Monitoring | N/A | N/A | Jan 9, 2025 | Active | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Dec 31, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2024 | Resolved | N/A |
| LEAD AND COPPER RULE REVISIONS | Monitoring | N/A | N/A | Oct 16, 2024 | Active | N/A |
| LEAD AND COPPER RULE REVISIONS | Health-Based | N/A | N/A | Oct 16, 2024 | Active | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2024 | Resolved | N/A |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Health-Based | N/A | 0.011 | Sep 30, 2024 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2024 | Resolved | N/A |
| E. COLI | Monitoring | 0 | N/A | Sep 26, 2024 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 26, 2024 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| E. COLI | Monitoring | 0 | N/A | Sep 26, 2024 | Active | Severe gastrointestinal illness; may be fatal in vulnerable populations |
| Public Notice | Monitoring | N/A | N/A | Aug 24, 2024 | Active | N/A |
| Public Notice | Monitoring | N/A | N/A | Jul 3, 2024 | Active | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Jun 30, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Mar 31, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Mar 31, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Mar 31, 2024 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Dec 31, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Sep 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2023 | Resolved | N/A |
| Nitrate-Nitrite | Health-Based | N/A | 11 | Jun 30, 2023 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | Eye and nose irritation; stomach discomfort |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Mar 31, 2023 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Consumer Confidence Rule | Monitoring | N/A | N/A | Oct 1, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 6 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 6 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 6 | Sep 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 6 | Jun 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 6 | Jun 30, 2022 | Resolved | N/A |
| Combined Radium (-226 and -228) | Health-Based | N/A | 6 | Jun 30, 2022 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrate-Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrate-Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrate-Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Nitrate-Nitrite | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Dec 31, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Radium (-226 and -228) | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Arsenic | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | Skin damage; circulatory system problems; increased risk of cancer |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Beta Particle Activity | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Gross Alpha, Excl. Radon and U | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Combined Uranium | Monitoring | N/A | N/A | Sep 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Revised Total Coliform Rule | Monitoring | N/A | N/A | Apr 30, 2021 | Resolved | N/A |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |
| Chlorine | Monitoring | N/A | N/A | Mar 31, 2021 | Resolved | Eye and nose irritation; stomach discomfort |